

# Neurology Specialty Testing Client Test Request

Client Information (requi	red)		Patient Information (require	ed)		
Client Name			Patient ID (Medical Record No.)	_		
Client Account No.			Patient Name (Last, First Middle)			
Client Phone	Client Order No.		Sex  Male Female	Birth Dat	e (mm-dd-yyyy)	
Street Address			Collection Date (mm-dd-yyyy)	Time	□ am	
City	State	ZIP Code	Street Address			
Submitting Healthcare	Professional In	formation	City	State	ZIP Code	
(required) Submitting/Referring Healthca	are Professional (Las	t, First)	Phone			
Fill in only if Call Back is requir	red.		Reason for Testing (required	<del>l</del> )		
Phone (with area code)	-					
National Provider Identificatio	n (NPI)					
*Fax number given must be from a fax HIPAA regulation.	machine that complies v	vith applicable				
"I hereby confirm that informed individual legally authorized to			ICD-10 Diagnosis Code			
or the individual's provider's of Signature		with this office	Note: It is a client's responsibility to mainta New York State Patients: Informed Conse			
Note: It is the client's responsibility to	maintain dagumantation	of the order	MCL Internal Use Only			
recte. It is the client's responsibility to	maintain documentation	or the order.				



# Ship specimens to:

Mayo Clinic Laboratories 3050 Superior Drive NW Rochester, MN 55905

Customer Service: 800-533-1710

# **Billing Information**

- An itemized invoice will be sent each month.
- Payment terms are net 30 days.

Call the Business Office with billing-related questions: 800-447-6424 (US and Canada) 507-266-5490 (outside the US)

# **Patient Information (required)**

Patient ID (Medical Record No.)	Client Account No.
Patient Name (Last, First Middle)	Client Order No.
Birth Date (mm-dd-yyyy)	

# **AUTOIMMUNE CNS AND** PARANEOPLASTIC DISORDERS Encephalopathy, Autoimmune/ Paraneoplastic Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA-B, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF, Septin-7, Neurochondrin, TRIM46, PDE10A) ☐ ENC2 Encephalopathy, Autoimmune/ Paraneoplastic Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA-B, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF, Septin-7, Neurochondrin, TRIM46, PDE10A) ☐ GBACS Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody by Cell Binding Assay, Serum ☐ GBACC Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody by Cell Binding Assay, Spinal Fluid ☐ MA2ES Ma2 Antibody by ELISA, Serum ☐ MA2EC Ma2 Antibody by ELISA, Spinal Fluid ☐ K11CS Kelch-Like Protein 11 Antibody, Cell Binding Assay, Serum ☐ K11CC Kelch-Like Protein 11 Antibody, Cell Binding Assay, Spinal Fluid ☐ GD65S Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum ☐ GD65C Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Spinal Fluid **Pediatric CNS Disorders** ☐ PCDEC Pediatric Autoimmune Encephalopathy/ CNS Disorders Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA-B, AQP4, DPPX, MGIuR1, PCA-Tr, ANNA-1, GAD65, GFAP, Neurochondrin) ☐ PCDES Pediatric Autoimmune Encephalopathy/ CNS Disorders Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA-B, AQP4, MOG, DPPX, MGIuR1, PCA-Tr, ANNA-1, GAD65, GFAP, Neurochondrin) Gamma-Amino Butyric Acid Type A ☐ GBACC (GABA-A) Receptor Antibody by Cell

AUTOIMMUNE VISION LOSS						
□ PVLE	Paraneoplastic Vision Loss Evaluation, Serum (RCVBS, CRMS)					
☐ RCVBS	Recoverin-IgG Antibody by Immunoblot,					

Serum

Binding Assay, Serum

Binding Assay, Spinal Fluid

Gamma-Amino Butyric Acid Type A

(GABA-A) Receptor Antibody by Cell

☐ GBACS

DEMENTIA	A Comment of the Comm		
Alzheimer's	s Disease		
☐ PT217	Phospho-Tau 217, Plasma		
☐ C2NAD	PrecivityAD, Plasma		
☐ C2AD2	PrecivityAD2, Plasma		
☐ AD2AR	PrecivityAD2, Reflex to Apolipoprotein E, Plasma		
☐ ADEVL	Alzheimer's Disease Evaluation, Spinal Fluid (Abeta42, total-Tau, p-Tau181, p-Tau181/Abeta42 ratio)		
☐ AMYR	Beta-Amyloid Ratio (1-42/1-40), Spinal Fluid		
☐ APOEG	Apolipoprotein E Genotyping, Blood		
Autoimmu	ne Dementia		
□ DMS2	Dementia, Autoimmune/Paraneoplastic Evaluation, Serum (NMDA, LGI1, CASPR2, AMPA, GABA-B, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA- 2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF, Neurochondrin, TRIM46, PDE10A)		
□ DMC2	Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid (NMDA, LGI1, CASPR2, AMPA, GABA-B, DPPX, mGluR1, PCA-Tr, IgLON5, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF, Neurochondrin, TRIM46, PDE10A)		
Rapidly Pro	ogressive Dementia		
□ RPDE	Rapidly Progressive Dementia Evaluation, Spinal Fluid (Abeta42, total-Tau, p-Tau181, p-Tau181/Abeta42 ratio, RT-QuIC Prion, total-Tau/p-Tau181 ratio)		
Creutzfeld	t-Jakob Disease		
□ CJDE	Creutzfeldt-Jakob Disease Evaluation, Spinal Fluid (RT-QuIC Prion, total-Tau, p-Tau181, total-Tau/p-Tau181 ratio)		
Frontotem	poral Dementia		
☐ C9ORF	C9orf72 Hexanucleotide Repeat, Molecular Analysis		
☐ AFTDP	Inherited Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Gene Panel (51 genes)		
□ CGPH	Custom Gene Panel, Hereditary, Next-Generation Sequencing (This test can be utilized to modify any of the above frontotemporal dementia multi-gene panels or to order a single gene from any of the above panels.)		
Gene List ID:			

CADASIL	
□ NTC3Z	NOTCH3 Gene, Full Gene Analysis
DEMYELIN	NATING DISEASE
□ CDS1	CNS Demyelinating Disease Evaluation, Serum (AQP4, MOG)
□ NMOFS	Neuromyelitis Optica (NMO)/ Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
□ MOGFS	Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum
☐ KCSF	Immunoglobulin Kappa Free Light Chain, Spinal Fluid
☐ MSP3	Multiple Sclerosis (MS) Profile, Serum and Spinal Fluid
DEVELOPI	MENTAL DELAY
□ BWRS	Beckwith-Wiedemann Syndrome/Russell- Silver Syndrome, Molecular Analysis, Varies
□ CDKZ	CDKN1C Gene, Full Gene Analysis, Varies
□ СМАСВ	Chromosomal Microarray, Congenital, Blood
☐ FXS	Fragile X Syndrome, Molecular Analysis
☐ PWAS	Prader-Willi/Angelman Syndrome, Molecular Analysis
☐ MCP2Z	MECP2 Gene, Full Gene Analysis
DYSAUTO	NOMIA
□ DYS2	Dysautonomia Autoimmune/ Paraneoplastic Evaluation, Serum (LG11, CASPR2, DPPX, AChR Ganglionic, ANNA-1, PCA-2, CRMP-5, AP3B2)
<b>EPILEPSY</b>	
Autoimmu	ne Epilepsy
□ EPS2	Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum (NMDA, LG11, CASPR2, AMPA, GABA-B, DPPX, mGluR1, PCA-Tr,

# CASPR2, AMPA, GABA-B, DPPX, mGluR1, PCA-Tr, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, Neurochondrin, TRIM46, PDE10A) GBACS Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody by Cell Binding Assay, Serum GBACC Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody by Cell Binding Assay, Spinal Fluid

ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-2,

CRMP-5, Amphiphysin, GAD65, GFAP,

Epilepsy, Autoimmune/Paraneoplastic

Evaluation, Spinal Fluid (NMDA, LGI1,

Neurochondrin, TRIM46, PDE10A)

☐ EPC2

# **Patient Information (required)**

Patient ID	(Medical Record No.)			Client Account No.		
Patient Na	ame (Last, First Middle)			Client Order No.		
Birth Date	(mm-dd-yyyy)					
Hereditary	Epilepsy	МІТОСНО	NDRIAL DIS	ORDERS	☐ ATAXP	Inherited Ataxia Gene Panel (198 genes)
☐ EPPAN	Comprehensive Epilepsy Gene Panel	☐ GDF15	Growth Diffe	erentiation Factor 15, Plasma	☐ PARDP	Inherited Parkinson Disease Gene Panel
□ нмер	(319 genes) Hemiplegic Migraine Gene Panel (9 genes)	□ DMITO	Mitochondri ddPCR, Varie	al DNA Deletion Heteroplasmy, es	□ ISPP	(94 genes) Inherited Spastic Paraplegia Gene Panel (128 genes)
☐ TSCP	Tuberous Sclerosis Gene Panel (2 genes)	☐ MITOP		al Full Genome Analysis eration Sequencing (NGS)	☐ HAD	Huntington Disease, Molecular Analysis
□ CSTB	CSTB Repeat Expansion Analysis  Custom Gene Panel, Hereditary	□ мміто	Mitochondri	al Nuclear Gene Panel eration Sequencing (NGS)	□ DRPL	Dentatorubral-Pallidoluysian Atrophy (DRPLA) Gene Analysis, Varies
	(This test can be utilized to modify any of the above panels or to order a single gene from any of the above panels.)	□ сміто	Combined M	Nitochondrial Analysis, al Full Genome and Nuclear	□ CGPH	Custom Gene Panel, Hereditary, Next-Generation Sequencing (This test can be utilized to modify
Gene List	Gene List ID:					any of the above peripheral neuropathy
FOLLOW-I	UP TESTING - NEUROIMMUNOLOGY		NT DISORDE	18		multi-gene panels or to order a single gene from any of the above panels.)
☐ PNEFS	Neuroimmunology Antibody Follow-up, Serum	Autoimmu  ☐ GLYCS		eptor Alpha1 IgG, Cell Binding	Gene Lis	t ID:
	Specify Antibody:	☐ GLYCC	Assay, Serum	n eptor Alpha1 IgG, Cell Binding	MYELOPA	ТНҮ
□ PNEFC	Neuroimmunology Antibody Follow-up, Spinal Fluid	☐ MA2ES	Assay, Spinal		☐ MAS1	Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum (AQP4, MOG, GABA-B,
	Specify Antibody:	☐ MA2ES		ly by ELISA, Spinal Fluid		DPPX, mGluR1, ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5,
MENUNIQUE		☐ MDS2		Disorder, Autoimmune/		Amphiphysin, GAD65, GFAP, NIF, Septin-7,
MENINGIT  ☐ CSFME	Meningitis/Encephalitis Pathogen Panel, PCR, Spinal Fluid		(NMDA, LGI1 DPPX, MGIul	tic Evaluation, Serum , CASPR2, AMPA, GABA-B, R1, VGCC-P/Q, PCA-Tr, IgLON5, NA-2, ANNA-3, AGNA-1, PCA-1,	☐ MAC1	AP3B2, Neurochondrin, TRIM46)  Myelopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid (AQP4, GABA-B, DPPX, mGluR1, ANNA-1, ANNA-2, ANNA-3,
☐ MSCSF	Bacteria, Virus, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid		PCA-2, CRMI GFAP, GRAF1	P-5, Amphiphysin, GAD65, I, ITPR1, KLHL11, NIF, Septin-5, 3B2, Neurochondrin, TRIM46,		AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GAD65, GFAP, NIF, Septin-7, AP3B2, Neurochondrin, TRIM46)
HEREDITARY HEARING LOSS			PDE10A)	obz, Neurochonann, Hannao,		
☐ AHLP	AudioloGene Hearing Loss Panel, Varies	☐ MDC2		Disorder, Autoimmune/ tic Evaluation, Spinal Fluid		GENERATION
WHOLE EX	WHOLE EXOME		(NMDA, LGI1	, CASPR2, AMPA, GABA-B,	☐ ASYNC	Alpha-Synuclein Aggregates, Spinal Fluid Neurofilament Light Chain, Plasma
☐ CMPRE	Family Member Comparator Specimen for Exome Sequencing, Varies		ANNA-2, ANI	R1, PCA-Tr, IgLON5, ANNA-1, NA-3, AGNA-1, PCA-1, PCA-2, aphiphysin, GAD65, GFAP,	NEUROM	
☐ WESPR	. 0		GRAF1, ITPR1	I, KLHL11, NIF, Septin-5, Septin-7,		cular Junction Disorders
□ WESMT	Test, Varies  Whole Exome and Mitochondrial Genome Sequencing, Varies	□ SPPS	Stiff-Person	Spectrum Disorders Evaluation,	☐ MGMR	Myasthenia Gravis Evaluation with Muscle- Specific Kinase (MuSK) Reflex, Serum
□ WESDX	Whole Exome Sequencing for Hereditary Disorders, Varies		with Rigidity	ogressive Encephalomyelitis and Myoclonus, Serum 5, DPPX, Amphiphysin)	☐ MGLE	Myasthenia Gravis/Lambert-Eaton Myasthenic Syndrome Evaluation, Serum
□ WESR	Whole Exome Sequencing Reanalysis,	□ SPPC		Spectrum Disorders Evaluation,	Stand-Alor	ne Antibodies
	Varies		with Rigidity	ogressive Encephalomyelitis and Myoclonus, Spinal Fluid 5, DPPX, Amphiphysin)	☐ ARBI	Acetylcholine Receptor (Muscle AChR) Binding Antibody, Serum
WHOLE GI		Hereditary	Movement D		☐ MUSK	Muscle-Specific Kinase (MuSK) Autoantibody, Serum
	Family Member Comparator Specimen for Genome Sequencing, Varies	FFRWB Friedreich Ataxia, Frataxin, Quantitative, Whole Blood		Autoimmu	ne Neuromuscular	
☐ WGSDX	Whole Genome Sequencing for Hereditary Disorders, Varies	☐ AFXN		axia, Repeat Expansion Analysis	Idiopathic I	nflammatory Myopathy
□ WGSR	Whole Genome Sequencing Reanalysis, Varies	□ SCAP		ellar Ataxia Repeat Expansion	☐ MSAES	Serum
		□ SCARA	Spinocerebe	ellar Ataxia Type 1, 2, 3, 6, or 7, nsion Analysis	□ NMS1	Necrotizing Myopathy Evaluation, Serum (HMGCR, SRP)
		Gene Lis	t ID:			

Patient l	nformation (required)					
Patient ID (Medical Record No.)			Client Account No.			
Patient Name (Last, First Middle)			Client Order No.			
Birth Date	(mm-dd-yyyy)					
Hereditary	Neuromuscular	Demyelinat	ing		□ czps	Clonazepam and 7-Aminoclonazepam,
_ *	PAN Comprehensive Neuromuscular DMNES Perip		Peripheral Ne	Peripheral Nervous System Demyelinating Jeuropathy, Autoimmune Evaluation, Serum		Serum Ethosuximide, Serum
Motor Neur			(Contactin-1)	gG CBA, GQ1b, IgG Disialo.	☐ ETX ☐ FELBA	Felbamate (Felbatol), Serum
☐ MNDP	Inherited Motor Neuron Disease			Disialo. GD1b, IgG Monos. onos. GM1, MAG IgM,	☐ GABA	Gabapentin, Serum
	Gene Panel (34 genes)		Neurofascin-		☐ LACO	Lacosamide, Serum
□ SOD1Z	SOD1 Gene, Full Gene Analysis	☐ MAGES		iated Glycoproteins (MAG)	☐ LAMO	Lamotrigine, Serum
☐ C9ORF	C9orf72 Hexanucleotide Repeat, Molecular Analysis	☐ CIDP	Chronic Infla	es (IgM), Serum mmatory Demyelinating	□ LEFLU	Leflunomide Metabolite (Teriflunomide), Serum
☐ SMNDX	MNDX Spinal Muscular Atrophy Diagnostic Assay,			neuropathy/Nodopathy erum (Contactin-1 IgG CBA,	□ LEVE	Levetiracetam, Serum
□ SBULB	Deletion/Duplication Analysis		Neurofascin-	155 IgG4)	☐ MEPHS	Mephobarbital and Phenobarbital, Serum
□ SBULB	Spinobulbar Muscular Atrophy (Kennedy Disease), Molecular Analysis	Ganglioside	s		□ омнс	Oxcarbazepine Metabolite, Serum
Myopathy		☐ GAES		Antibodies Evaluation, Serum sialo. GD1b, IgM Disialo. GD1b,	☐ PERAM	Perampanel, Serum
☐ RABMP	Inherited Rhabdomyolysis and			iM1, IgM Monos. GM1)	□ PBR	Phenobarbital, Serum
Metabolic Myopathy Panel (84 genes)		☐ GQ1ES	Ganglioside GQ1b Antibody, IgG, ELISA,	□ PNYA	Phenytoin, Total, Serum	
Neuromuscular Junction		Serum			☐ PGN	Pregabalin, Serum
☐ CMSP	Inherited Congenital Myasthenic Syndrome Gene Panel (28 genes)		Peripheral No		☐ PRMB	Primidone and Phenobarbital, Serum
☐ LGCMP	Inherited Limb-Girdle Muscular Dystrophy		PMP22 Gene Analysis	e, Large Deletion/Duplication	□ RUFI	Rufinamide, Serum
	and Congenital Myasthenic Syndrome Gene Panel (65 genes)	☐ PEPAN	•	ive Peripheral Neuropathy	☐ SECOS	Secobarbital, Serum Topiramate, Serum
Muscular Dystrophy		☐ IMSNP		tor and Sensory Neuropathy	□ TMP	Trimethoprim, Serum
☐ MDYSP	Inherited Muscular Dystrophy Gene Panel		Gene Panel (8	37 genes)	□ VALPA	Valproic Acid, Total, Serum
	(75 genes)	☐ IMNP	Inherited Mo (26 genes)	tor Neuropathy Gene Panel	□ ZONI	Zonisamide, Serum
☐ LGCMP	Inherited Limb-Girdle Muscular Dystrophy and Congenital Myasthenic Syndrome	☐ ISNP		sory Neuropathy Gene Panel	Pharmacogenomics	
□ EDMDP	Gene Panel (65 genes)  Inherited Emery-Dreifuss Gene Panel (7 genes)	□ SORD	Sorbitol and I	Xylitol, Quantitative, Random,	☐ PGXQP	Focused Pharmacogenomics Panel (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, SLCO1B1, VKORC1,
☐ DMDZ	DMD Gene, Full Gene Analysis	☐ TTRZ		Il Gene Analysis (1 gene)		CYP4F2, and rs12777823)
☐ DBMD	Duchenne/Becker Muscular Dystrophy,  DMD Gene, Large Deletion/Duplication  □ DWPAN Comprehe				☐ CARBR	Carbamazepine Hypersensitivity Pharmacogenomics, Varies
Analysis  Hyperexcitable Muscle Disease		Gene Panel (2		211 genes)	□ сомто	Catechol-O-Methyltransferase (COMT) Genotype
☐ SMCP	Inherited Skeletal Muscle Channelopathy	□ SEP9Z		ne, Full Gene Analysis (1 gene)	☐ 1A2Q	Cytochrome P450 1A2 Genotype
□ 0M0I	Gene Panel (5 genes)	□ CGPH		e Panel, Hereditary,	☐ 2C19R	Cytochrome P450 2C19 Genotype
☐ CGPH	Custom Gene Panel, Hereditary		Next-General	tion Sequencing	☐ 2C9QT	Cytochrome P450 2C9 Genotype
	(This test can be utilized to modify any of the neuromuscular multi-gene panels or to order a single gene from any of the		any of the ab	be utilized to modify ove peripheral neuropathy anels or to order a single	□ 2D6Q	Cytochrome P450 2D6 Comprehensive Cascade
	above panels.)			y of the above panels.)	□ 3A4Q	Cytochrome P450 3A4 Genotype
Gene List	t ID:	Gene List	: ID:		□ 3A5Q	Cytochrome P450 3A5 Genotype
NEUROPA'	THV	SLEEP DIS	ORDERS		□ NAT2Q	N-Acetyltransferase 2 (NAT2) Genotype
				pocretin-1, Spinal Fluid	☐ TPNUQ	Thiopurine Methyltransferase ( <i>TPMT</i> ) and Nudix Hydrolase ( <i>NUDT15</i> ) Genotyping
Autoimmui	ne Neuropathy	L OKANA	OTEXIII-W/11A/	Journal I Iulu	_	and Hadix Hydrolase (NOD Ho) denotyping

## Axonal

☐ AIAES

Axonal Neuropathy, Autoimmune/ Paraneoplastic Evaluation, Serum (LGI1, CASPR2, IgLON5, ANNA-1, ANNA-3, AGNA-1, PCA-1, PCA-2, CRMP-5, Amphiphysin, GFAP, NIF, AP3B2)

# THERAPEUTIC TESTING / DRUG MONITORING

# **Antiepileptic Drugs**

☐ BRIVA Brivaracetam, Plasma ☐ CARTA Carbamazepine, Total, Serum

☐ CDP Chlordiazepoxide and Metabolite, Serum

☐ CLOBZ Clobazam and Metabolite, Serum

□ ETX	Ethosuximide, Serum
☐ FELBA	Felbamate (Felbatol), Serum
□ GABA	Gabapentin, Serum
□ LACO	Lacosamide, Serum
☐ LAMO	Lamotrigine, Serum
□ LEFLU	Leflunomide Metabolite (Teriflunomide), Serum
□ LEVE	Levetiracetam, Serum
☐ MEPHS	Mephobarbital and Phenobarbital, Serum
□ омнс	Oxcarbazepine Metabolite, Serum
☐ PERAM	Perampanel, Serum
□ PBR	Phenobarbital, Serum
□ PNYA	Phenytoin, Total, Serum
□ PGN	Pregabalin, Serum
☐ PRMB	Primidone and Phenobarbital, Serum
□ RUFI	Rufinamide, Serum
☐ SECOS	Secobarbital, Serum
□ ТОРІ	Topiramate, Serum
□ тмр	Trimethoprim, Serum
□ VALPA	Valproic Acid, Total, Serum
□ ZONI	Zonisamide, Serum
Pharmacog	enomics
□ PGXQP	Focused Pharmacogenomics Panel (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, SLC01B1, VKORC1, CYP4F2, and rs12777823)
□ CARBR	Carbamazepine Hypersensitivity Pharmacogenomics, Varies
□ сомто	Catechol-O-Methyltransferase (COMT) Genotype
☐ 1A2Q	Cytochrome P450 1A2 Genotype
☐ 2C19R	Cytochrome P450 2C19 Genotype
☐ 2C9QT	Cytochrome P450 2C9 Genotype
□ 2D6Q	Cytochrome P450 2D6 Comprehensive Cascade
T 7440	Cytochrome P450 3A4 Genotype
□ 3A4Q	
☐ 3A4Q	Cytochrome P450 3A5 Genotype
	Cytochrome P450 3A5 Genotype N-Acetyltransferase 2 (NAT2) Genotype
□ 3A5Q	

**ADDITIONAL TESTS** 

(INDICATE TEST ID AND NAME)